Generic atorvastatin is as effective as the brand-name drug (LIPITOR®) in lowering cholesterol levels: a cross-sectional retrospective cohort study

Springer Science and Business Media LLC - 2017
Alexander Loch1, Jan Philipp Bewersdorf1, Daniel Kofink2, Dzafir Ismail1, Imran Zainal Abidin1, Ramesh Singh Veriah1
1Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia
2Laboratory of Experimental Cardiology, Department of Cardiology, Division of Heart and Lungs, University Medical Center Utrecht, Utrecht, The Netherlands

Tóm tắt

In a world of ever increasing health care costs, generic drugs represent a major opportunity to ensure access to essential medicines for people who otherwise would be unable to afford them. However, some clinicians and patients are still questioning the safety and effectiveness of generic formulations compared to the proprietary drugs necessitating further systematic research analyzing the generic drugs’ efficacy. Our objective was to compare the lipid lowering effects of generic and branded atorvastatin. This cross-sectional, retrospective cohort study was conducted at the University of Malaya Medical Centre from 1 May 2013 until 30 May 2013. We analyzed the lipid profiles (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) of 629 patients before and at least 3 months after switching them from proprietary atorvastatin (Lipitor®) to generic atorvastatin (atorvastatin calcium from Ranbaxy Laboratories, Inc.). We also investigated if there was any difference in the effectiveness of both atorvastatin formulations in various ethnic groups. 266 patients were included in this study. When comparing the median values we found no statistically significant differences (Wilcoxon signed-rank test; p < 0.05) between proprietary and generic atorvastatin in lowering total cholesterol (4.60 mmol/l pre-transition vs. 4.50 mmol/l post-transition; p = 0.583), LDL-cholesterol (2.42 mmol/l vs. 2.41 mmol/l; p = 0.923) and triglycerides (1.50 mmol/l vs. 1.50 mmol/l; p = 0.513). While there was a statistically significant (p = 0.009) difference in HDL-cholesterol levels favouring proprietary atorvastatin, the extent of this change (1.26 mmol/l vs. 1.25 mmol/l) was deemed not to be clinically relevant. There was no statistically significant difference when analyzing the effects on various ethnic groups. Substituting proprietary atorvastatin for its generic formulation atorvastatin calcium does not result in a less effective management of hyperlipidemia. Our findings lend support to the approach of lowering health care costs by switching patients from branded drugs to their less expensive generic analogues.

Từ khóa


Tài liệu tham khảo

Kelly C. The balance between innovation and competition: the Hatch–Waxman Act, the 2003 amendments, and beyond. Food Drug Law J. 2011;66(3):417–78.

Shrank WH, Liberman JN, Fischer MA, Girdish C, Brennan TA, Choudhry NK. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31–8.

Jackevicius CA, Chou MM, Ross JS, Shah ND, Krumholz HM. Generic atorvastatin and health care costs. N Engl J Med. 2012;366(3):201–4.

Justice.gov DoJ. Generic drug manufacturer ranbaxy pleads guilty and agrees to Pay $500 Million to resolve false claims allegations, cGMP violations and false statements to the FDA. 2013. https://www.justice.gov/opa/pr/generic-drug-manufacturer-ranbaxy-pleads-guilty-and-agrees-pay-500-million-resolve-false. Accessed 20 May 2017.

Loftus P. Ranbaxy halts production of generic Lipitor. Wall Str J. 2012. http://www.wsj.com/news/articles/SB10001424127887323751104578149383396925280. Accessed 20 May 2017.

Jackevicius CA, Tu JV, Krumholz HM, Austin PC, Ross JS, Stukel TA, et al. Comparative effectiveness of generic atorvastatin and Lipitor® in patients hospitalized with an acute coronary syndrome. J Am Heart Assoc. 2016;5(4):e003350.

Rahalkar AR, Ban MR, Hegele RA. Clinical equivalence of proprietary and generic atorvastatin in lipid clinic patients. Can J Cardiol. 2013;29(4):418–22.

Kim SH, Park K, Hong SJ, Cho YS, Sung JD, Moon GW, et al. Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Clin Ther. 2010;32(11):1896–905.

Ong LM, Punithavathi N, Lena YL, Mahanim O, Leekha S, Storvas Clinical Trial Study G. Long-term efficacy and safety of a generic atorvastatin in usual clinical care setting. Med J Malaysia. 2011;66(3):214–9.

Caldeira D, Fernandes RM, Costa J, David C, Sampaio C, Ferreira JJ. Branded versus generic clopidogrel in cardiovascular diseases: a systematic review. J Cardiovasc Pharmacol. 2013;61(4):277–82.

Manzoli L, Flacco ME, Boccia S, D’Andrea E, Panic N, Marzuillo C, et al. Generic versus brand-name drugs used in cardiovascular diseases. Eur J Epidemiol. 2016;31(4):351–68.

Rathe J, Andersen M, Jarbol DE, dePont Christensen R, Hallas J, Sondergaard J. Generic switching and non-persistence among medicine users: a combined population-based questionnaire and register study. PLoS ONE. 2015;10(3):e0119688.

Olsson E, Kalvemark Sporrong S. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract. 2012;20(6):377–83.

Drozdowska A, Hermanowski T. Exploring factors underlying the attitude of community pharmacists to generic substitution: a nationwide study from Poland. Int J Clin Pharm. 2016;38(1):162–70.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả